Testing Immunotherapy and Chemotherapy Before Surgery for Locally Advanced Cervical Cancer
Tests two immunotherapy drugs with chemotherapy before surgery in adults with cervical cancer.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Key facts
- Where
- Fuzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 70 with locally advanced cervical cancer who have not yet had systemic treatment. It tests drugs given before surgery.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- FIGO 2018 stage IB3, IIA2, or IIIC1r. Cancer type: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix. Measurable lesions by RECIST v1.1.
- Earlier treatment
- No systemic therapy at the time of enrollment.
Main reasons for not taking part
- Another cancer within the past 3 years
- Active autoimmune disease needing systemic therapy
- Previous allogeneic tissue or solid organ transplant
- Active HBV, HCV, or HIV infection
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07055399, who can take part
Where in China
- Fujian Cancer HospitalFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Cancer Hospital
- Trial code
- NCT07055399
- Record updated
- 11 September 2025
- Original description
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1/CTLA-4 dual blocker-combined with chemotherapy for LACC.Read full original descriptionShow less
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1/CTLA-4 dual blocker-combined with chemotherapy for LACC.
Inclusion: 1、Written informed consent; 2、18-70 years old; 3、Adequate organ function and ECOG of 0 ~1; 4、Without systemic therapy at the time of enrollment; 5、FIGO 2018 stage IB3, IIA2, or IIIC1r; 6、Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix; 7、Measurable lesions could be defined by RECIST v1.1; 8、Willing to get blood/ tumor tissue tested; 9、Patients who observed the rules about the scheduled visit, study schedule, and medical examination; 10、The function of major organs is normal, and the following criteria are met:; 10.1 Blood routine examination must meet: (no blood transfusion within 14 days); Hb≥90g/L:; ANC≥1.5x10\^9/L; PLT≥100x10\^9/L; 10.2 The biochemical examination must meet the following standards BIL < 1.5 × ULN; ALT and AST < 2.5xULN; ALB≥ 28 g/L; 11、Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures.
Exclusion: 9、Drug or alcohol abuse; 1、History of other malignancies within 3 years; 3、Active autoimmune disease, which needs systemic therapy; 4、Uncontrolled infection, which needs systemic therapy; 5、History of allogeneic tissue/solid organ transplant; 6、Serious illness, such as severe mental disorders, cardiac disease, coagulation disorders, digestive system disease, etc; 7、Active HBV, HCV, or HIV infection; 2、Participate in other clinical trials at the same time; 8、Pregnant or lactating female patients; 10、 Unable or unwilling to sign the informed consent.